Seminars in Nuclear Medicine
Volume 32, Issue 2 , Pages 110-122 , April 2002

Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience

  • Roelf Valkema

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
    • Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
    • Department of Medical Sciences, University Hospital, Uppsala, Sweden
    • Department of Tyco Healthcare, Petten, The Netherlands
    • ,
  • Marion de Jong

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
    • Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
    • Department of Medical Sciences, University Hospital, Uppsala, Sweden
    • Department of Tyco Healthcare, Petten, The Netherlands
    • ,
  • Willem H. Bakker

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
    • Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
    • Department of Medical Sciences, University Hospital, Uppsala, Sweden
    • Department of Tyco Healthcare, Petten, The Netherlands
    • ,
  • Wout A.P. Breeman

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
    • Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
    • Department of Medical Sciences, University Hospital, Uppsala, Sweden
    • Department of Tyco Healthcare, Petten, The Netherlands
    • ,
  • Peter P.M. Kooij

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
    • Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
    • Department of Medical Sciences, University Hospital, Uppsala, Sweden
    • Department of Tyco Healthcare, Petten, The Netherlands
    • ,
  • Pieternella J. Lugtenburg

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
    • Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
    • Department of Medical Sciences, University Hospital, Uppsala, Sweden
    • Department of Tyco Healthcare, Petten, The Netherlands
    • ,
  • Frank H. de Jong

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
    • Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
    • Department of Medical Sciences, University Hospital, Uppsala, Sweden
    • Department of Tyco Healthcare, Petten, The Netherlands
    • ,
  • Arjan Christiansen

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
    • Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
    • Department of Medical Sciences, University Hospital, Uppsala, Sweden
    • Department of Tyco Healthcare, Petten, The Netherlands
    • ,
  • Boen L.R. Kam

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
    • Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
    • Department of Medical Sciences, University Hospital, Uppsala, Sweden
    • Department of Tyco Healthcare, Petten, The Netherlands
    • ,
  • Wouter W. de Herder

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
    • Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
    • Department of Medical Sciences, University Hospital, Uppsala, Sweden
    • Department of Tyco Healthcare, Petten, The Netherlands
    • ,
  • Mats Stridsberg

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
    • Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
    • Department of Medical Sciences, University Hospital, Uppsala, Sweden
    • Department of Tyco Healthcare, Petten, The Netherlands
    • ,
  • Jan Lindemans

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
    • Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
    • Department of Medical Sciences, University Hospital, Uppsala, Sweden
    • Department of Tyco Healthcare, Petten, The Netherlands
    • ,
  • Geert Ensing

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
    • Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
    • Department of Medical Sciences, University Hospital, Uppsala, Sweden
    • Department of Tyco Healthcare, Petten, The Netherlands
    • ,
  • Eric P. Krenning

      Affiliations

    • Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    • Department of Hetology, Erasmus MC, Rotterdam, The Netherlands
    • Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands
    • Department of Medical Sciences, University Hospital, Uppsala, Sweden
    • Department of Tyco Healthcare, Petten, The Netherlands
    • Corresponding Author InformationAddress reprint requests to Eric P. Krenning, MD, Department of Nuclear Medicine, Erasmus University Centre, Rotterdam, 3015GD Rotterdam, The Netherlands.

References 

  1. Bakker WH, Albert R, Bruns C, et al. [111In-DTPA-D-Phe1]-Octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabeling and in vitro validation. Life Sci. 1991;49:1583–1591
  2. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–731
  3. Krenning EP, Kooij PP, Bakker WH, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci. 1994;733:496–506
  4. Janson ET, Westlin JE, Ohrvall U, et al. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors. J Nucl Med. 2000;41:1514–1518
  5. De Jong M, Bernard BF, De Bruin E, et al. Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun. 1998;19:283–288
  6. McLean JR, Wilkinson D. The radiation dose to cells in vitro from intracellular indium-111. Biochem Cell Biol. 1989;67:661–665
  7. Krenning EP, Bakker WH, Kooij PP, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med. 1992;33:652–658
  8. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–122
  9. van Uden A, Steinmeijer MVJ, de Swart J, et al. Imaging with octreoscan: Haste makes waste. Eur J Nucl Med. 1999;26:1022
  10. Stridsberg M, Hellman U, Wilander E, et al. Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: Development of a specific radioimmunoassay for chromogranin A and its fragments. J Endocrinol. 1993;139:329–337
  11. Guignat L, Bidart JM, Nocera M, et al. Chromogranin A and the alpha-subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma. Br J Cancer. 2001;84:808–812
  12. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207–214
  13. Mignon M. Natural history of neuroendocrine enteropancreatic tumors. Digestion. 2000;62:51–58
  14. Larsson G, von Essen L, Sjoden PO. Health-related quality of life in patients with endocrine tumours of the gastrointestinal tract. Acta Oncol. 1999;38:481–490
  15. Larsson G. Quality of life in patients with gastrointestinal tumours. In: Thesis. Uppsala, Sweden: Uppsala University; 2001;
  16. McCarthy KE, Woltering EA, Espenan GD, et al. In situ radiotherapy with 111In-pentetreotide: Initial observations and future directions. Cancer J Sci Am. 1998;4:94–102
  17. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: A review. Digestion. 2000;62:84–91
  18. Cornelius A, Murren J, Zoghbi S, et al. In-111-octreotide therapy: Phase I–II trial. J Nucl Med. 1999;40:19P
  19. Tiensuu Janson^E, Eriksson B, Oberg K, et al. Treatment with high dose [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors: Evaluation of therapeutic and toxic effects. Acta Oncol. 1999;38:373–377
  20. Caplin ME, Mielcarek W, Buscombe JR, et al. Toxicity of high-activity 111In-octreotide therapy in patients with disseminated neuroendocrine tumours. Nucl Med Commun. 2000;21:97–102
  21. McCarthy KE, Woltering EA, Anthony LB. In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives. Q J Nucl Med. 2000;44:88–95
  22. Otte A, Mueller-Brand J, Dellas S, et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet. 1998;351:417–418
  23. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med. 1999;26:1439–1447
  24. Paganelli G, Zoboli S, Cremonesi M, et al. Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide: Preliminary report in cancer patients. Cancer Biother Radiopharm. 1999;14:477–483
  25. Smith MC, Liu J, Chen T, et al. Octreo Ther: Ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy. Digestion. 2000;62:69–72
  26. Waldherr C, Pless M, Maecke HR, et al. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol. 2001;12:941–945
  27. Paganelli G, Zoboli S, Cremonesi M, et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med. 2001;28:426–434
  28. Valkema R, Jamar F, Bakker WH, et al. Safety and efficacy of [Y-90-DOTA,Tyr(3)]octreotide (Y-90-SMT487: OCTREOTHERTM) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study. Eur J Nucl Med. 2001;28:1025P
  29. Kwekkeboom DJ, Bakker WH, Kooij PPM, et al. [177Lu-DOTA0,Tyr3]octreotate: Comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med. 2001;28:1319–1325
  30. Slooter GD, Breeman WA, Marquet RL, et al. Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver. Int J Cancer. 1999;81:767–771
  31. Capello A, Krenning EP, Bernard HF, et al. Peptide receptor radionuclide therapy (PRRT) using somatostatin analogs. J Nucl Med. 2001;42:125P
  32. Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol. 1996;59:45–51
  33. Brincker H, Hansen HS, Andersen AP. Induction of leukemia by 131-I treatment of thyroid carcinoma. Br J Cancer. 1973;28:232–237
  34. Hall P, Boice JD, Berg G, et al. Leukaemia incidence after iodine-131 exposure. Lancet. 1992;340:1–4
  35. de Vathaire F, Sclumberger M, Delisle MJ, et al. Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer. 1997;75:734–739
  36. Oomen SP, Hofland LJ, van Hagen PM, et al. Somatostatin receptors in the haematopoietic system. Eur J Endocrinol. 2000;143(suppl 1):S9–S14
  37. Brady HB, Brenner BM, Lieberthal W. Acute renal failure. In: Brenner BM editors. Brenner and Rector's The Kidney. Philadelphia, PA: WB Saunders; 1995;p. 1200–1252
  38. Zhu LJ, Krempels K, Bardin CW, et al. The localization of messenger ribonucleic acids for somatostatin receptors 1, 2, and 3 in rat testis. Endocrinology. 1998;139:350–357
  39. Pierik FH, Vreeburg JT, Stijnen T, et al. Serum inhibin B as a marker of spermatogenesis. J Clin Endocrinol Metab. 1998;83:3110–3114
  40. Wichers M, Benz E, Palmedo H, et al. Testicular function after radioiodine therapy for thyroid carcinoma. Eur J Nucl Med. 2000;27:503–507
  41. Moertel CG, Kvols LK, O'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68:227–232

PII: S0001-2998(02)80029-0

doi: 10.1053/snuc/2002.31025

Seminars in Nuclear Medicine
Volume 32, Issue 2 , Pages 110-122 , April 2002

Article Tools